相关实验视频
Updated: Aug 7, 2026

13:01
Anti-Nuclear Antibody Screening Using HEp-2 Cells
Published on: June 23, 2014
血管炎和抗中性人细胞质自身抗体与甲治疗相关
K M Dolman1, R O Gans, T J Vervaat
1Central Laboratory, Netherlands Red Cross Blood Transfusion Service, Amsterdam.
Lancet (London, England)
|September 11, 1993
概括
甲 (PTU) 可以引起血管炎,这是一个罕见的疾病. 这项研究在患有PTU诱导的血管炎的患者中发现了抗中性粒细胞质抗体 (ANCA),该抗体在药物停用后消失.
科学领域:
- 类风湿病学 类风湿病学
- 内分泌学 在内分泌学.
- 免疫学 免疫学 免疫学
背景情况:
- 甲酸 (PTU) 是一种用于治疗甲状腺功能障碍症的药物.
- 血管炎,血管炎症是一种罕见但严重的并发症,与PTU治疗有关.
- 抗中性粒细胞质抗体 (ANCA) 与各种血管性疾病有关.
研究的目的:
- 调查在PTU治疗期间发生血管炎的患者中ANCA的存在和意义.
- 确定ANCA水平,PTU治疗和临床结果之间的相关性.
主要方法:
- 来自6名患有PTU诱导血管炎的患者的血清样本被分析为ANCA.
- 评估了ANCA的具体目标,包括人类中性粒细胞弹性酶 (HNE),蛋白酶3 (PR3) 和髓氧化酶 (MPO).
- 在PTU戒断后,对临床症状和ANCA度进行了监测.
主要成果:
- 在所有六名研究患者中检测到ANCA对HNE,PR3和MPO的检测.
- 在停止PTU后观察到ANCA度的显著下降.
- 在药物停止后,血管性症状完全消失.
结论:
- ANCA,特别是针对HNE,PR3和MPO,可以作为PTU诱导的血管炎的生物标志物.
- 停用甲甲是一种有效的策略,用于管理这种罕见的并发症.
- 需要进一步的研究来阐明ANCA在PTU相关血管炎中的确切病原性作用.
相关概念视频
Myasthenia Gravis: Overview and Treatment
Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which leads...
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which leads...
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab (Humira),...
Gastritis-II: Pathophysiology
Gastritis is marked by disruption of the mucosal barrier that usually protects the stomach tissue from digestive juices and manifests in acute and chronic forms.
In acute gastritis, the gastric mucosa becomes swollen and red and undergoes superficial erosion. Superficial ulceration may lead to bleeding.
In chronic gastritis, persistent or repeated insults lead to chronic inflammatory changes and, eventually, thinning or atrophy of the gastric tissue.
Gastritis can stem from various causes, each...
In acute gastritis, the gastric mucosa becomes swollen and red and undergoes superficial erosion. Superficial ulceration may lead to bleeding.
In chronic gastritis, persistent or repeated insults lead to chronic inflammatory changes and, eventually, thinning or atrophy of the gastric tissue.
Gastritis can stem from various causes, each...
Hypersensitivity Reactions: Cytolytic Reactions
Type II hypersensitivity involves IgG and IgM antibodies targeting cell surface antigens, leading to cell destruction. This can occur through complement activation, antibody-dependent cell-mediated cytotoxicity (ADCC), or acting as opsonins for phagocytosis. When excessive, these reactions cause significant tissue damage.Drug-induced hemolytic anemia is a common example, where drugs like penicillin or cephalosporins bind to red blood cells, forming drug-protein complexes. These complexes...
Myasthenia Gravis ll: Pathophysiology
The disease process of myasthenia gravis begins at the neuromuscular junction, where antibodies attack key proteins needed for muscle activation. This immune reaction weakens signal transmission, leading to the characteristic muscle fatigue and weakness that define the condition.Immune-Mediated DamageIn most individuals, antibodies target acetylcholine receptors (AChRs) on the postsynaptic membrane of muscle cells. By blocking acetylcholine binding, these antibodies prevent the nerve signal...
Hypersensitivity Reactions: Immune-Complex Reactions
Type III hypersensitivity reactions occur when antigen–antibody complexes form and activate the complement system. Normally, these complexes help the clearance of antigens by phagocytes and red blood cells. However, when large numbers of immune complexes are present, they can deposit in tissues—particularly in the walls of blood vessels—leading to inflammation and tissue injury. These deposits trigger complement activation and neutrophil recruitment, resulting in serum sickness, a systemic...

